The regulatory factor to aberrant epigenetic state in ovarian cancer and target molecule.

• Project/Area Number: 23659769
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: Tohoku University
• Principal Investigator: YAEGASHI Nobuo 東北大学, 医学(系)研究科(研究院), 教授 (00241597)
• Co-Investigator(Kenkyū-buntansha): OTSUKI Takeo 東北大学, 大学院医学系研究科, 非常勤講師 (40531330)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000); Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 卵巣癌 / 分子標的遺伝子 / DNAメチル化 / ＤＮＡメチル化

Research Abstract

Human ovarian cancer (HOC) is characterized by complex genetic and epigenetic alterations. We found that MAT2A (methyonine adenosyltransferase 2A), which act as a synthetase of the methyl donor was highly expressed and heavily hypomethylation in the promoter. Experiment of MAT2A siRNA and inhibit cycloroicine was effective on the HOC growth. We found that the target molucule of MAT2A was tumor suppressor gene, RB1. This finding is that RB1 is the new tumor marker of HOC.

Research Products

• [Journal Article] A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). (2014)
  • Author(s): Shoji T, Takatori E, Kaido Y, Omi H, Yokoyama Y, Mizunuma H, Kaiho M, Otsuki T, Takano T, Yaegashi N, Nishiyama H, Fujimori K, Sugiyama T.
  • Journal Title: Cancer Chemother Pharmacol Volume: - Issue: 5 Pages: 895-901
  • DOI: 10.1007/s00280-014-2418-8
  • Peer Reviewed
• [Journal Article] Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer (2014)
  • Author(s): Yokoyama Y, Futagami M, Watanabe J, Sato N, Terada Y, Miura F, Sugiyama T, Takano T, Yaegashi N, Kojimahara T, Kurachi H, Nishiyama H, Fujimori K, Tase T, Mizunuma H
  • Journal Title: Mol Clin Oncol Volume: 2(2), (PubMed PMID: 24649335) Pages: 212-218
  • Peer Reviewed
• [Journal Article] A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). (2014)
  • Author(s): Shoji T, Takatori E, Kaido Y, Omi H, Yokoyama Y, Mizunuma H, Kaiho M, Otsuki T, Takano T, Yaegashi N, Nishiyama H, Fujimori K, Sugiyama T.
  • Journal Title: Cancer Chemother Pharmacol Volume: accepted
  • Peer Reviewed
• [Journal Article] Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. (2014)
  • Author(s): Yokoyama Y, Futagami M, Watanabe J, Sato N, Terada Y, Miura F, Sugiyama T, Takano T, Yaegashi N, Kojimahara T, Kurachi H, Nishiyama H, Fujimori K, Tase T, Mizunuma H
  • Journal Title: Mol Clin Oncol Volume: 2(2) Pages: 212-218
  • Peer Reviewed
• [Journal Article] Efficacy of recombinant human soluble thrombomodulin in severe postpartum hemorrhage with disseminated intravascular coagulation. (2013)
  • Author(s): Sugawara J, Suenaga K, Hoshiai T, Sato T, Nishigohri H, Nagase S and Yaegashi N.
  • Journal Title: Clin Appl Thromb/Hemost Volume: 19(5) Issue: 5 Pages: 557-561
  • DOI: 10.1177/1076029612443305
  • Peer Reviewed
• [Journal Article] the BOSHI Study Group. Daily serial hemodynamic data during pregnancy and seasonal (2012)
  • Author(s): Metoki H, Ohkubo T, Obara T, Akutsu K, Yamamoto M, Ishikuro M, Sakurai K, Iwama N, Katagiri M, Sugawara J, Hirose T, Sato M, Kikuya M, Yagihashi K, Matsubara Y, Yaegashi N, Mori S, Suzuki M, Imai Y
  • Journal Title: variation : the BOSHI study. Clin Exp Hypertens Volume: (In press) Issue: 4 Pages: 290-6
  • DOI: 10.3109/10641963.2012.681086
  • Peer Reviewed
• [Journal Article] Assessment of maternal heart-rate variability during labor using wavelet based power spectral analysis (2012)
  • Author(s): Suzuki N, Sugawara J, Kimura Y, Nagase S, Okamura K and Yaegashi N
  • Journal Title: Gynecol Obstet Invest Volume: 74(1) Issue: 1 Pages: 35-40
  • DOI: 10.1159/000336064
  • Peer Reviewed
• [Journal Article] MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma (2012)
  • Author(s): Hiroki E, Akahira J, et al
  • Journal Title: Int J Cancer Volume: (印刷中) Issue: 4 Pages: 395-404
  • DOI: 10.1002/ijc.27345
  • Peer Reviewed
• [Journal Article] Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer. (Tohoku Gynecologic Cancer Unit 101 Group Study) (2011)
  • Author(s): Shoji T, Kurachi H
  • Journal Title: Int J Gynecol Cancer Volume: 1(1) Issue: 1 Pages: 44-50
  • DOI: 10.1097/igc.0b013e3181ffbe9f
  • Peer Reviewed
• [Journal Article] Validation of the histologic grading for ovarian clear cell adenocarcinoma : a retrospective multi-institutional study by the Japan clear cell carcinoma study group (2011)
  • Author(s): Yamamoto S, Kurachi H
  • Journal Title: Int J Gynecol Pathol Volume: 30(2) Issue: 0 Pages: 129-138
  • DOI: 10.1097/pgp.0b013e3181f71264
  • Peer Reviewed
• [Journal Article] MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. (2011)
  • Author(s): Hiroki E, Suzuki F, Akahira JI, Nagase S, Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H, Yaegashi N.
  • Journal Title: Int J Cancer. Volume: Epub ahead of print
  • Peer Reviewed
• [Journal Article] Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study). (2011)
  • Author(s): Shoji T, Takatori E, Omi H, Kumagai S, Yoshizaki A, Yokoyama Y, Mizunuma H, Fujimoto T, Takano T, Yaegashi N, Tase T, Nakahara K, Kurachi H, Nishiyama H, Sugiyama T.
  • Journal Title: Internationa Journal of Gynecologic Cancer. Volume: 21(1) Pages: 44-50
  • Peer Reviewed
• [Journal Article] Validation of the histological grading for ovarian clear-cell adenocarcinoma: a retrospective multi-institutional study of Japan Clear Cell Carcinoma Study Group (2011)
  • Author(s): Yamamoto S, Kasajima A, Takano M, Yaegashi N, Suzuki M, Kuzuya K, Kigawa J, Tsuda H, Kurachi H, Kikuchi Y, Sugiyama T, Tsuda H, Moriya T.
  • Journal Title: International Journal of Gynecologic Pathology Volume: 30(2) Pages: 129-138
  • Peer Reviewed
• [Presentation] 八重樫伸生卵巣がん転移を標的とした創薬 (2013)
  • Author(s): 北谷和之
  • Organizer: 第12回日本婦人科分子標的研究会
  • Place of Presentation: 奈良
  • Year and Date: 2013-07-05
• [Presentation] Paclitaxel plus carboplatin for advanced or recurrent carcinosarcomas of the uterus (2011)
  • Author(s): Tadao Takano, Hideki Tokunaga, Takeo Otsuki, Kosuke Yoshinaga, Satoru Nagase, Hitoshi Niikura, Kisyoshi Ito, Takashi Takeda, Nobuo Yaegashi, Tadahiro Shoji, Toru Sugiyama, Toshio Fujimoto, Yukihiro Terada, Kenji Nakahara, Tomohisa Kurachi, Takashi Mastumoto, Masamichi Hiura, Shinya Sato, Muneaki Shimada, Jyunzo Kigawa
  • Organizer: Japanese Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study. ESGO
  • Place of Presentation: Milano(Italy)
• [Presentation] Paclitaxel plus carboplatin for advanced or recurrent carcinosarcomas of the uterus. Japanese Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study (2011)
  • Author(s): Tadao Takano
  • Organizer: ESGO
  • Place of Presentation: Milan, Italy
• [Presentation] 卵巣がん転移を標的とした創薬
  • Author(s): 北谷和之、八重樫伸生
  • Organizer: 第１２回日本婦人科分子標的研究会
  • Place of Presentation: 奈良